Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood

Blood

Volumn 104, Issue 7, 2004, Pages 2134-2142

  Kriangkum, Jitra ^b   Taylor, Brian J ^b   Treon, Steven P ^b   Mant, Michael J ^b   Belch, Andrew R ^b   Pilarski, Linda M ^a  

^a CROSS CANCER INSTITUTE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; IMMUNOGLOBULIN D; IMMUNOGLOBULIN M;

ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BONE MARROW; CLINICAL ARTICLE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; DNA SEQUENCE; GENE MUTATION; GENE SEQUENCE; GENE SWITCHING; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN GENE; IMMUNOGLOBULIN VARIABLE REGION; MULTIGENE FAMILY; PERTHES DISEASE; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VALIDATION PROCESS;

EID: 4644230890     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-11-4024     Document Type: Article

References (46)

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30:110-115.
2. Dimopoulos MA, Galani E, Matsouka C. Waldenstrom's macroglobulinemia. Hematol Oncol Clin North Am. 1999;13:1351-1366.
3. Bartl R, Frisch B, Mahl G, et al. Bone marrow histology in Waldenstrom's macroglobulinaemia: clinical relevance of subtype recognition. Scand J Haematol. 1983;31:359-375.
4. Wagner SD, Martinelli V, Luzzatto L. Similar patterns of V kappa gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstrom's macroglobulinemia, and myeloma. Blood. 1994;83:3647-3653.
5. Sahota SS, Forconi F, Ottensmeier CH, et al. Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood. 2002;100:1505-1507.
6. Kriangkum J, Taylor BJ, Mant MJ, Treon SP, Belch AR, Pilarski LM. The malignant clone in Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:132-135.
7. Ciric B, VanKeulen V, Rodriguez M, Kyle RA, Gertz MA, Pease LR. Clonal evolution in Waldenstrom macroglobulinemia highlights functional role of B-cell receptor. Blood. 2001;97:321-323.
8. Shiokawa S, Suehiro Y, Uike N, Muta K, Nishimura J. Sequence and expression analyses of mu and delta transcripts in patients with Waldenstrom's macroglobulinemia. Am J Hematol. 2001;68:139-143.
9. Owen RG, Johnson SA, Morgan GJ. Waldenstrom's macroglobulinaemia: laboratory diagnosis and treatment. Hematol Oncol. 2000;18:41-49.
10. Papamichael D, Norton AJ, Foran JM, et al. Immunocytoma: a retrospective analysis from St Bartholomew's Hospital - 1972 to 1996. J Clin Oncol. 1999;17:2847-2853.
11. Jensen GS, Andrews EJ, Mant MJ, Vergidis R, Ledbetter JA, Pilarski LM. Transitions in CD45 isoform expression indicate continuous differentiation of a monoclonal CD5+ CD11b+ B lineage in Waldenstrom's macroglobulinemia. Am J Hematol. 1991;37:20-30.
12. Jensen GS, Poppema S, Mant MJ, Pilarski LM. Transition in CD45 isoform expression during differentiation of normal and abnormal B cells. Int Immunol. 1989;1:229-236.
13. Pilarski LM, Andrews EJ, Serra HM, Ledbetter JA, Ruether BA, Mant MJ. Abnormalities in lymphocyte profile and specificity repertoire of patients with Waldenstrom's macroglobulinemia, multiple myeloma, and IgM monoclonal gammopathy of undetermined significance. Am J Hematol. 1989;30:53-60.
14. Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med. 1998;188:1679-1689.
15. Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood. 1995;85:3378-3404.
16. Dong HY, Shahsafaei A, Dorfman DM. CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naive B cells. Leuk Lymphoma. 2002;43:1855-1858.
17. Guikema JE, Hovenga S, Vellenga E, et al. CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease. Br J Haematol. 2003;121:36-43.
18. Lefranc MP. IMGT databases, web resources and tools for immunoglobulin and T cell receptor sequence analysis, http://imgt.cines.fr. Leukemia. 2003;17:260-266.
19. Kabat EA, Bilofsky H, Wu TT. Variable Regions of Immunoglobulin Chains: Tabulations and Analyses of Amino Acid Sequences. Cambridge, MA: Bolt Beranek and Newman; 1991.
20. Lossos IS, Tibshirani R, Narasimhan B, Levy R. The inference of antigen selection on Ig genes. J Immunol. 2000;165:5122-5126.
21. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445.
22. Szczepek AJ, Seeberger K, Wizniak J, Mant MJ, Belch AR, Pilarski LM. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood. 1998;92:2844-2855.
23. Taylor BJ, Pittman JA, Seeberger K, et al. Intraclonal homogeneity of clonotypic immunoglobulin M and diversity of nonclinical post-switch isotypes in multiple myeloma: insights into the evolution of the myeloma clone. Clin Cancer Res. 2002;8:502-513.
24. Aoki H, Takishita M, Kosaka M, Saito S. Frequent somatic mutations in D and/or JH segments of Ig gene in Waldenstrom's macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter's syndrome but not in common CLL. Blood. 1995;85:1913-1919.
25. Wang X, Stollar BD. Immunoglobulin VH gene expression in human aging. Clin Immunol. 1999;93:132-142.
26. Rosenquist R, Lindstrom A, Holmberg D, Lindh J, Roos G. V(H) gene family utilization in different B-cell lymphoma subgroups. Eur J Haematol. 1999;62:123-128.
27. Coupland SE, Foss HD, Anagnostopoulos I, Hummel M, Stein H. Immunoglobulin VH gene expression among extranodal marginal zone B-cell lymphomas of the ocular adnexa. Invest Ophthalmol Vis Sci. 1999;40:555-562.
28. Thorselius M, Walsh S, Eriksson I, et al. Somatic hypermutation and V(H) gene usage in mantle cell lymphoma. Eur J Haematol. 2002;68:217-224.
29. Dorner T, Foster SJ, Brezinschek HP, Lipsky PE. Analysis of the targeting of the hypermutational machinery and the impact of subsequent selection on the distribution of nucleotide changes in human VHDJH rearrangements. Immunol Rev. 1998;162:161-171.
30. Dunn-Walters DK, Spencer J. Strong intrinsic biases towards mutation and conservation of bases in human IgVH genes during somatic hypermutation prevent statistical analysis of antigen selection. Immunology. 1998;95:339-345.
31. Zemlin M, Bauer K, Hummel M, et al. The diversity of rearranged immunoglobulin heavy chain variable region genes in peripheral blood B cells of preterm infants is restricted by short third complementarity-determining regions but not by limited gene segment usage. Blood. 2001;97:1511-1513.
32. Rosner K, Winter DB, Tarone RE, Skovgaard GL, Bohr VA, Gearhart PJ. Third complementarity-determining region of mutated VH immunoglobulin genes contains shorter V, D, J, P, and N components than non-mutated genes. Immunology. 2001;103:179-187.
33. Raaphorst FM, Timmers E, Kenter MJ, Van Tol MJ, Vossen JM, Schuurman RK. Restricted utilization of germ-line VH3 genes and short diverse third complementarity-determining regions (CDR3) in human fetal B lymphocyte immunoglobulin heavy chain rearrangements. Eur J Immunol. 1992;22:247-251.
34. Leung DT, Yam NW, Chui YL, Wong KC, Lim PL. A human and a mouse anti-idiotypic antibody specific for human T14(+) anti-DNA antibodies reconstructed by phage display. Gene. 2000;255:373-380.
35. Allen RC, Armitage RJ, Conley ME, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science. 1993;259:990-993.
36. Fuleihan R, Ramesh N, Geha RS. Role of CD40-CD40-Ligand interaction in Ig-isotype switching. Curr Opin Immunol. 1993;5:963-967.
37. Ferrari S, Giliani S, Insalaco A, et al. Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Natl Acad Sci U S A. 2001;98:12614-12619.
38. Garcia-Perez MA, Paz-Artal E, Corell A, et al. Mutations of CD40 ligand in two patients with hyper-IgM syndrome. Immunobiology. 2003;207:285-294.
39. Revy P, Muto T, Levy Y, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2). Cell. 2000;102:565-575.
40. Minegishi Y, Lavoie A, Cunningham-Rundles C, et al. Mutations in activation-induced cytidine deaminase in patients with hyper IgM syndrome. Clin Immunol. 2000;97:203-210.
41. Imai K, Slupphaug G, Lee WI, et al. Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat Immunol. 2003;4:1023-1028.
42. Nardini E, Rizzi S, Capello D, et al. Most immunoglobulin heavy chain switch mu rearrangements in B-cell chronic lymphocytic leukemia are internal deletions. FEBS Lett. 2002;518:119-123.
43. Sahota SS, Garand R, Mahroof R, et al. V(H) gene analysis of IgM-secreting myeloma indicates an origin from a memory cell undergoing isotype switch events. Blood. 1999;94:1070-1076.
44. San Miguel JF, Vidriales MB, Ocio E, et al. Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:187-195.
45. Jacobi AM, Odendahl M, Reiter K, et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2003;48:1332-1342.
46. Vilpo J, Tobin G, Hulkkonen J, et al. Surface antigen expression and correlation with variable heavy-chain gene mutation status in chronic lymphocytic leukemia. Eur J Haematol. 2003;70:53-59.